Kite Pharma to Present at IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing the Next Generation of Cancer Immunotherapies Conference

SANTA MONICA, Calif.Sept. 24, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Marc Better Ph.D., Vice President, Product Sciences, will present during the opening plenary session at IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing the Next Generation of Cancer Immunotherapies Conference, taking place in Alexandria, VASeptember 30 - October 1, 2015. Dr. Better's presentation, "Overcoming Challenges for Engineered Autologous T Cell Therapy," will take place on Wednesday, September 30, 2015, at 8:15am Eastern Time. In addition, a podcast and article related to Dr. Better's participation in the upcoming event are available via the Calendar of Events section of Kite's website at

About Kite Pharma, Inc.

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACTâ„¢) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit

CONTACT: Kite Pharma

         Cynthia M. Butitta

         Chief Financial Officer and Chief Operating Officer


         For Media: Justin Jackson

         For Investor Inquiries: Lisa Burns

         Burns McClellan


Source: Kite Pharma, Inc.

News Provided by Acquire Media